Tumor Biology-Guided Radiotherapy Treatment Planning: Gross Tumor Volume Versus Functional Tumor Volume

Seminars in Nuclear Medicine

Volumn 38, Issue 2, 2008, Pages 105-113

  Guha, Chandan ^a   Alfieri, Alan ^a   Blaufox, M Donald ^a   Kalnicki, Shalom ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; DNA; RADIOISOTOPE;

CANCER RADIOTHERAPY; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DNA METHYLATION; GENETIC MARKER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ONCOGENE; PHOSPHORYLATION; POSITRON EMISSION TOMOGRAPHY; REVIEW; TREATMENT PLANNING; TUMOR VOLUME;

DNA METHYLATION; HUMANS; KERATINS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; ONCOGENES; PHOSPHORYLATION; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 38549147708     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2007.12.001     Document Type: Review

References (105)

1. Mah D., and Chen C.C. Image guidance in radiation oncology treatment planning: The role of technologies on the planning process. Semin Nucl Med 38 (2008) 114-118
2. Brunetti J., Caggiano A., Rosenbluth B., et al. Technical aspects of positron emission tomography/computed tomography fusion planning. Semin Nucl Med 38 (2008) 129-136
3. Bourland J.D., and Shaw E.G. The evolving role of biological imaging in stereotactic radiosurgery. Technol Cancer Res Treat 2 (2003) 135-239
4. Kim M.K., Ryu J.S., Kim S.B., et al. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 43 (2007) 1385-1391
5. Klopp A.H., Chang J.Y., Tucker S.L., et al. Intrathoracic patterns of failure for non-small-cell lung cancer with positron-emission tomography/computed tomography-defined target delineation. Int J Radiat Oncol Biol Phys 69 (2007) 1405-1416
6. Erasmus J.J., Macapinlac H.A., and Swisher S.G. Positron emission tomography imaging in nonsmall-cell lung cancer. Cancer 110 (2007) 2155-2168
7. Podoloff D.A., and Macapinlac H.A. PET and PET/CT in management of the lymphomas. Radiol Clin North Am 45 (2007) 689-696 vii
8. Yang WT, Le-Petross HT, Macapinlac H, et al: Inflammatory breast cancer: PET/CT, MRI, mammography, and sonography findings. Breast Cancer Res Treat, in press
9. Erasmus J.J., Munden R.F., Truong M.T., et al. Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: A confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. J Thorac Oncol 1 (2006) 478-486
10. Vallabhajosula S. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: An overview of radiochemistry and mechanisms of tumor localization. Semin Nucl Med 37 (2007) 400-419
11. Je S.K., Ahn M.I., and Park Y.H. Detection of a small lung cancer hidden in pneumoconiosis with progressive massive fibrosis using F-18 fluorodeoxyglucose PET/CT. Clin Nucl Med 32 (2007) 247-248
12. Kim S.Y., Lee S.W., Nam S.Y., et al. The feasibility of 18F-FDG PET scans 1 month after completing radiotherapy of squamous cell carcinoma of the head and neck. J Nucl Med 48 (2007) 373-378
13. Ahn P.H., and Garg M.K. Positron emission tomography/computed tomography for target delineation in head and neck cancers. Semin Nucl Med 38 (2008) 141-148
14. Macapinlac H. Clinical applications of positron emission tomography/computed tomography treatment planning. Semin Nucl Med 38 (2008) 137-140
15. Schöder H., and Ong S.C. Fundamentals of molecular imaging: Rationale and applications with relevance for radiation oncology. Semin Nucl Med 38 (2008) 119-128
16. Langen K.J., Jarosch M., Muhlensiepen H., et al. Comparison of fluorotyrosines and methionine uptake in F98 rat gliomas. Nucl Med Biol 30 (2003) 501-508
17. Jager P.L., Vaalburg W., Pruimet J., et al. Radiolabeled amino acids: Basic aspects and clinical applications in oncology. J Nucl Med 42 (2001) 432-445
18. 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer. Cancer Res 61 (2001) 110-117
19. 18]F-labeled choline analogs as oncologic PET tracers. J Nucl Med 42 (2001) 1805-1814
20. 18F]fluorocholine. J Label Compd Radiopharm 48 (2005) S281
21. 11C] choline. J Nucl Med 38 (1997) 842-847
22. 18F]-Fluoroethylcholine for cancer imaging with PET: Synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 43 (2002) 187-199
23. 18F]dOC). Nucl Med Biol 31 (2004) 851-858
24. Yoshimoto M., Waki A., Obata A., et al. Radiolabeled choline as a proliferation marker: Comparison with radiolabeled acetate. Nucl Med Nucl Med Biol 31 (2004) 859-865
25. 11C-acetate PET imaging of prostate cancer: Detection of recurrent disease at PSA relapse. J Nucl Med 44 (2003) 549-555
26. 18F]-Fluoroacetate, an analogue of C-11 acetate for tumor imaging. J Nucl Med 44 (2003) 296
27. Schoder H., and Larson S.M. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 34 (2004) 274-292
28. 18F]fluoro-L-dopa and its metabolism in vivo-a critical review. Int J Rad Appl Instrum B 19 (1992) 149-158
29. 18F-DOPA positron emission tomography for tumor detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28 (2001) 64-71
30. 18F DOPA whole body PET-initial results. Radiology 222 (2002) 507-512
31. 18]F-FDOPA PET. J Nucl Med 45 (2004) 1161-1167
32. 18F]fluoro-α-methyl tyrosine: A potential tumor-detecting agent. J Nucl Med 39 (1998) 663-667
33. 18F-radiolabeling, as a tracer for the non-invasive monitoring of the biodistribution of drugs against AIDS. ABST J Fluorine Chem 55 (1991) 283-289
34. 18F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol 27 (2000) 143-156
35. Mankoff D.A., Shields A.F., and Krohn K.A. PET imaging of cellular proliferation. Radiol Clin N Am 43 (2005) 153-167
36. Shields A.F., Grierson J.R., Dohmen B.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4 (1998) 1334-1336
37. 18F]FLT) in pancreatic cancer cell lines. Eur J Nucl Med Mol Imaging 29 (2002) 1174-1181
38. Grierson J.R., Schwartz J.L., Muzi M., et al. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: Validations for positron emission tomography. Nucl Med Biol 31 (2004) 829-837
39. 18F-FLT and thymidine analogs: Promise and pitfalls. J Nucl Med 44 (2003) 1432-1434
40. 18F labeled fluoronitroimidazoles: Potential in vivo markers of hypoxic tissue. Int J Radiat Appl Instrum 37 (1986) 599-605
41. Rasey J.S., Grunbaum Z., Magee S., et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 111 (1987) 292-304
42. Rajendran J.G., Schwartz D.L., O'Sullivan J., et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 12 (2006) 5435-5441
43. 18F]FETNIM: A potential marker for PET. J Nucl Med 42 (2001) 1397-1404
44. 18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia. J Nucl Med 40 (1999) 1072-1079
45. 18F-fluoroazomycin arabinoside. J Nucl Med 46 (2005) 106-113
46. 18F-FAZA PET predicts success of hypoxia-directed radiochemotherapy using tirapazamine. J Nucl Med 48 (2007) 973-980
47. Foo S.S., Abbott D.F., Lawrentschuk N., et al. Functional imaging of intra-tumoral hypoxia. Mol Imaging Biol 6 (2004) 291-305
48. Kiesewetter D.O., Kilbourn M.R., Landvatter S.W., et al. Preparation of four fluorine-18 labeled estrogens and their selective uptakes in target tissues of immature rats. J Nucl Med 25 (1984) 1212-1221
49. Lim J.L., Zheng L., Berridge M.S., et al. The use of 3-methoxymethyl-l6β, 17β-epiestriol-O-cyclic sulfone as the precursor in the synthesis of F-l 8-16α-fluoroestradiol. Nucl Med Biol 23 (1996) 911-915
50. Mankoff D.A., Tewson T.J., and Eary J.F. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16α-fluoroestradiol (FES). Nucl Med Biol 24 (1997) 341-348
51. 18F]FES) for estrogen receptor imaging by positron emission tomography. Nucl Med Biol 34 (2007) 459-464
52. Seimbille Y., Ali H., and van Lier J.E. Synthesis of 2, 16α- and 4,16α difluoroestradiols and their 11β-methoxy derivatives as potential estrogen receptor-binding radiopharmaceuticals. J Chem Soc Perkin Trans 1 (2002) 657-663
53. Van de Wiele C., De Vos F., Slegers G., et al. Radiolabeled estradiol derivatives to predict response to hormonal treatment in breast cancer: A review. Eur J Nucl Med 27 (2000) 1421-1433
54. Haseman M.K., Rosenthal S.A., Kipper S.L., et al. Central abdominal uptake of indium-111 capromab pendetide (ProstaScint) predicts for poor prognosis in patients with prostate cancer. Urology 70 (2007) 303-308
55. Mohammed A.A., Shergill I.S., Vandal M.T., et al. ProstaScint and its role in the diagnosis of prostate cancer. Expert Rev Mol Diagn 7 (2007) 345-349
56. Lacy G.L., Soderdahl D.W., and Hernandez J. Optimal cost-effective staging evaluations in prostate cancer. Curr Urol Rep 8 (2007) 190-196
57. Choi J.Y., Jang K.T., Shim Y.M., et al. Prognostic significance of vascular endothelial growth factor expression and microvessel density in esophageal squamous cell carcinoma: Comparison with positron emission tomography. Ann Surg Oncol 13 (2006) 1054-1062
58. Beer A.J., Hauber R., Sarbia M., et al. PET using 18Fgalacto-RGD identifies the level of integrin alphavbeta3 expression in man. Clin Can Res 12 (2006) 3942-3949
59. Beer A.J., Haubner R., Goebel M., et al. Biodistribution and pharmacokinetics of the alphavbeta3 selective tracer 18F Galacto-RGD in cancer patients. J Nuc Med 46 (2005) 1333-1341
60. 18F-fluoride PET/CT. J Nucl Med 45 (2004) 272-278
61. 99mTc-methylene diphosphonate. Semin Nucl Med 31 (2001) 28-49
62. Hamaoka J., Madewell E., Podoloff D.A., et al. Bone imaging in metastatic breast cancer. J Clin Oncol 22 (2004) 2942-2953
63. Blankenberg F.G., Katsikis P.D., Tait J.F., et al. Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J Nuclear Med 40 (1999) 184-191
64. Shulkin B.L., Hutchinson R.J., Castle V.P., et al. Neuroblastoma: Positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 199 (1996) 743-750
65. 18F] fluoro-17β-oestradiol in breast cancer: Correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 2 (1996) 933-939
66. Winnard P., and Raman V. Real time non-invasive imaging of receptor-ligand interactions in vivo. J. Cellular Biochem 90 (2003) 454-463
67. Jacobs A.H., Thomas A., Kracht L.W., et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 46 (2005) 1948-1958
68. Wester H.-J. Nuclear imaging probes: From bench to bedside. Clin Cancer Res 13 (2007) 3470-3481
69. Gupta N., Price P.M., and Aboagye E.O. PET for in vivo pharmacokinetic and pharmacodynamic measurements. Eur J Cancer 38 (2002) 2094-2107
70. Kenny L.M., Vigushin D.M., Al-Nahhas A., et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: Evaluation of analytical methods. Cancer Res 65 (2005) 10104-10112
71. Pnwar P., Iznaga-Escobar N., Mishra P., et al. Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy. Cancer Biol Ther 4 (2005) 854-860
72. Kang K.W., Min J.J., Chen X., et al. Comparison of [14C]FMAU, [3H]FEAU, [14C]FIAU, and [3H]PCV for monitoring reporter gene expression of wild type and mutant herpes simplex virus type 1 thymidine kinase in cell culture. Mol Imaging Biol 7 (2005) 296-303
73. Robinson M.K., Doss M., Shaller C., et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 65 (2005) 1471-1478
74. Zanzonico P.B., Finn R., Pentlow K.S., et al. PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. J Nucl Med 45 (2004) 1966-1971
75. Choi S.J., Kim J.S., Kim J.H., et al. [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 32 (2005) 653-659
76. Juhasz C., Chugani D.C., Muzik O., et al. In vivo uptake and metabolism of alpha-[11C]methyl-L-tryptophan in human brain tumors. J Cereb Blood Flow Metab 26 (2006) 345-357
77. Floeth F.W., Pauleit D., Wittsack H.J., et al. Multimodal metabolic imaging of cerebral gliomas: Positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg 102 (2005) 318-327
78. Pauleit D., Floeth F., Hamacher K., et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128 (2005) 678-687
79. Weckesser M., Langen K.J., Rickert C.H., et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumors. Eur J Nucl Med Mol Imaging 32 (2005) 422-429
80. Shulkin B.L., Wieland D.M., Baro M.E., et al. PET hydroxyephedrine imaging of neuroblastoma. J Nucl Med 37 (1996) 16-21
81. Shulkin B.L., Wieland D.M., Castle V.P., et al. Carbon-11 epinephrine PET imaging of neuroblastoma. J Nucl Med 40 (1999) 129P
82. Franzius C., Hermann K., Weckesser M., et al. Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic system: Feasibility study and comparison with 123I-MIBG SPECT-CT. J Nucl Med 47 (2006) 1635-1642
83. Brink I., Schaefer O., Walz M., et al. Fluorine-18 DOPA PET imaging of paraganglioma syndrome. Clin Nucl Med 31 (2006) 39-41
84. Vaidyanathan G., Affleck D.J., and Zalutsky M.R. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med 36 (1995) 644-650
85. Carroll V.A., Glaser M., Aboagye E., et al. Imaging vascular endothelial growth factor in vivo with positron emission tomography. Br J Cancer 83 (2000) P6
86. 124I]iododeoxyuridine. Cancer Res 60 (2000) 624-635
87. Dimitrakopoulou A., Strauss L.G., Clorius J.H., et al. Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma. J Nucl Med 34 (1993) 1075-1081
88. Katzenellenbogen J.A., Welch M.J., and Dehdashti F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res 17 (1997) 1573-1576
89. 18F]fluoro-labeled progestins for PET. Int J Rad Appl Instrum [A] 42 (1991) 471-474
90. Liu A., Carlson K.E., and Katzenellenbogen J.A. Synthesis of high affinity fluorine-substituted ligands for the androgen receptor. Potential agents for imaging prostatic cancer by positron emission tomography. J Med Chem 35 (1992) 2113-2129
91. Liu A., Dence C.S., Welch M.J., et al. Fluorine-18-labelled androgens: Radiochemical synthesis and tissue distribution and studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer. J Nucl Med 33 (1992) 724-734
92. Blankenberg F.G., Katsikis P.D., Tait J.F., et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci USA 95 (1998) 6349-6354
93. Aboagye E.O., Kelson A.B., Tracy M., et al. Preclinical development and current status of the fluorinated 2- nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2- nitro-1-imidazolyl) acetamide (SR 4554, CRC 94/17):a non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography. Anticancer Drug Des 13 (1998) 703-730
94. Lemmer K., Ahnert-Hilger G., Hopjner M., et al. Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells. Life Sci 71 (2002) 667-678
95. 1-octreotide in 194 carcinoid patients: Vienna University experience, 1993 to 1998. J Clin Oncol 18 (2000) 1331-1336
96. 18F]fluoroethylspiperone, a new dopamine receptor-binding tracer for positron emission tomography. Nucl Med Biol 13 (1986) 617-624
97. 3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol 29 (2002) 147-157
98. 7]-α -MSH, an α-melanocyte stimulating hormone analogue. Nucl Med Biol 24 (1997) 171-178
99. Wu A.M., Williams L.E., Zieran L., et al. Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging. Tumor Target 4 (1999) 47-58
100. Wu A.M., Yazaki P.J., Tsai S.W., et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci USA 97 (2000) 8495-8500
101. Shaul M., Abourbeh G., Jacobson O., et al. Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer. Bioorg Med Chem 12 (2004) 3421-3429
102. Mishani E., Abourbeh G., Jacobson O., et al. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors. J Med Chem 48 (2005) 5337-5348
103. Rajendran J.G., and Mankoff D.A. Beyond detection: Novel applications for PET imaging to guide cancer therapy. J Nucl Med 48 (2007) 855-856
104. Rosenberg S.A. Progress In human tumour Immunology and Immunotherapy. Nature 411 (2001) 380-384
105. Bigbee W., and Herberman R.B. Tumor markers and immunodiagnosis. In: Kufe D.W., Pollock R.E., Weichselbaum R.R., et al. (Eds). Cancer Medicine. (ed 6) (2003), BC Decker, Hamilton, ON, Canada 209-220